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Abstract
Background: Mutations in the bone morphogenetic protein receptor 2 (BMPR2) gene can lead to idiopathic
pulmonary arterial hypertension (IPAH). This study prospectively screened for BMPR2 mutations in a large cohort of
PAH-patients and compared clinical features between BMPR2 mutation carriers and non-carriers.
Methods: Patients have been assessed by right heart catheterization and genetic testing. In all patients a detailed
family history and pedigree analysis have been obtained. We compared age at diagnosis and hemodynamic
parameters between carriers and non-carriers of BMPR2 mutations. In non-carriers with familial aggregation of PAH
further genes/gene regions as the BMPR2 promoter region, the ACVRL1, Endoglin, and SMAD8 genes have been
analysed.
Results: Of the 231 index patients 22 revealed a confirmed familial aggregation of the disease (HPAH), 209
patients had sporadic IPAH. In 49 patients (86.3% of patients with familial aggregation and 14.3% of sporadic IPAH)
mutations of the BMPR2 gene have been identified. Twelve BMPR2 mutations and 3 unclassified sequence variants
have not yet been described before. Mutation carriers were significantly younger at diagnosis than non-carriers
(38.53 ± 12.38 vs. 45.78 ± 11.32 years, p < 0.001) and had a more severe hemodynamic compromise. No gene
defects have been detected in 3 patients with HPAH.
Conclusion: This study identified in a large prospectively assessed cohort of PAH- patients new BMPR2 mutations,
which have not been described before and confirmed previous findings that mutation carriers are younger at
diagnosis with a more severe hemodynamic compromise. Thus, screening for BMPR2 mutations may be clinically
useful.
Introduction
Pulmonary arterial hypertension (PAH) is a rare vascular
disorder characterised by increased pulmonary vascular
resistance and right heart failure. PAH can be idiopathic
(IPAH), heritable (HPAH) or associated with other con-
ditions (APAH) as connective tissue diseases, congenital
heart diseases, portal hypertension, drug or toxin expo-
sure [1,2]. Heterozygous germline mutations in the bone
morphogenetic protein type 2 receptor (BMPR2)h a v e
been identified as a gene underlying HPAH in approxi-
mately 10 to 40% of patients with apparently sporadic
disease [1,3-6] and in 58% to 74% of patients with famil-
ial PAH [1,4,6,7]. In total 298 different mutations in
BMPR2 have been identified so far in independent
patients including those with a known PAH family his-
tory, sporadic disease and PAH associated with other
diseases [1]. In a few PAH patients mutations in other
genes participating in the BMPR2 signalling pathway
have been identified, as Activin A receptor type II-like 1
(ACVRL1, also called ALK1)[ 8 ] ,Endoglin [9], and
SMAD8 [10]. Nevertheless, there is still a small
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in which no gene defects can be detected so far [7,11].
HPAH patients carrying a BMPR2 mutation develop
the disease approximately 10 years earlier than non-car-
riers, with more severe hemodynamic changes [6,12-15]
and a reduced response to acute vasodilator testing
[6,12,14-16]. Patients carrying ACVRL1 or Endoglin
mutations have been characterised to be of younger age
at diagnosis and death as patients without mutations
[14]. A recent study of Austin et al [17] showed that
HPAH female patients with missense mutations in the
BMPR2 gene had a more severe disease than patients
with truncating mutations. These publications indicate
that the clinical phenotype of PAH can be affected by
the type of mutation. However, most data comparing
clinical features between BMPR2 mutation carriers and
non-carriers have been obtained from registries as from
the French Network of Pulmonary Hypertension
[6,13-15], and from centres in the United States as the
New York Presbyterian Pulmonary Hypertension Center
[12], the Utah Pulmonary Hypertension Genetics Project
[16] or the Vanderbilt University School of Medicine,
Nashville, Tennessee [7,17,18] and are retrospective in
design. The genetic mechanism of PAH remains unclear
in those families in which no BMPR2 mutation can be
detected.
Therefore, the aim of this study was to evaluate hemo-
dynamic parameters and genetic status in a large Ger-
man cohort of patients using a prospective design. The
frequency of known BMPR2 mutations has been ana-
lysed and a detailed search for new BMPR2 mutations
has been performed. In this study, we present 12 new
BMPR2 mutations and 3 unclassified variants which
have not been described before. Furthermore, we
describe the clinical features of families with confirmed
familial aggregation of PAH but no detectable mutations
of the BMPR2 gene and tested these families for muta-
tions of the genes ACVRL1, Endoglin, and SMAD8.
Materials and methods
Study Population
This prospective study investigated adult patients (≥ 18
years) with confirmed sporadic IPAH or familial HPAH
between January 2006 and December 2009, who agreed
to a genetic testing and from whom EDTA-blood was
obtained. Patients have been seen in the centres of pul-
monary hypertension (PH) of Heidelberg and Giessen
and underwent complete clinical and genetic work-up.
In all patients a right heart catheterization and a
detailed family history was obtained and a three to four
generation pedigree was constructed. For deceased rela-
tives, medical records were reviewed when available and
the diagnosis of PAH was based on the criteria used for
i n d e xp a t i e n t sa sw e l la so nt h er e s u l t so ft h ep o s t
mortem examination. Familial disease has been postu-
lated when PAH was diagnosed in at least two family
members. Sporadic IPAH was stated when family history
and medical records of family members were negative.
The Ethics Committees of the Medical Faculties of the
Universities of Heidelberg and Giessen approved the
protocol of this study, and the family members gave
their written informed consent. All participating patients
and family members underwent genetic counselling. The
study was part of the European Projects “Pulmotension”
which belongs to the 6th European Framework.
Mutation analysis of the BMPR2 gene
EDTA-blood samples were collected for genetic analysis
in all patients and from all family members, if available.
Human genomic DNA was prepared from peripheral
blood lymphocytes. The complete coding sequence and
exon/intron boundaries of the BMPR2 gene from each
individual were amplified and analysed by DHPLC and/
or direct sequencing as previously described [4]. HPAH
patients without an obvious BMPR2 mutation were also
analysed for mutations in the BMPR2 promoter, the
ACVRL1 gene, Endoglin gene, and SMAD8 gene. In
HPAH cases all first degree relatives were investigated
for the mutation identified in the index patient. Primer
sequences and PCR conditions are available upon
request. Standard DNA sequencing reactions were per-
formed using version 1.1 of Big Dye terminator cycle
sequencing kit (Applied Biosystems Inc., Darmstadt) and
were analysed on a Genetic Analyzer 3100 (Applied Bio-
systems Inc., Darmstadt). Pathogenicity of identified
sequence alterations were assessed by use of the pro-
gram MutationTaster http://www.mutationtaster.org/
and by ESEfinder 3.0 software http://rulai.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi.
Screening for larger rearrangements was performed
with the SALSA Multiplex Ligation-dependent Probe
Amplification (MLPA) P093-B1 HHT/PPH1 probe mix
kit (MRC-Holland BV, Amsterdam, The Netherlands).
The mutation nomenclature refers to the NCBI
human BMPR2 nucleotide sequence (NCBI:
NM_001204) and is expressed following the standard
recommendations of the Association for Molecular
Pathology Training and Education Committee [19] with
the A of the ATG start codon denoted as +1 and the
initiator methionine as codon 1.
Results
Study Population
Between January 2006 and December 2009 in total 262
patients agreed to participate in the study and EDTA-
blood has been stored for genetic analysis. Thirty-one
patients had to be excluded due to several reasons. In
23 patients the further diagnostic work-up revealed a
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patients the clinical data have been incomplete and in
another 5 patients not enough blood for genetic analysis
has been obtained. Thus, the study group for a complete
genetic work-up consisted of 231 patients. All investi-
gated patients were of Caucasian origin. About 91% of
the analysed patients included in this study were of Ger-
man ancestry, 4.8% were sent from different European
countries (as Spain, Belgium, Netherlands, Sweden, Italy,
and Eastern Europe), 1.3% were of Arabian ancestry and
2.6% of Turkish ancestry.
Genetic disposition to PAH in the study population
Of the 231 PAH index patients 22 (9.5%) revealed a
confirmed familial aggregation of the disease with at
least one further affected family member. The remaining
209 patients (90.5%) with negative family history have
been classified as sporadic IPAH cases (Figure 1). In 49
patients of the 231 PAH index patients (21.2%) includ-
ing 19 of the 22 familial (86.4%) and in 30 of the 209
(14.4%) apparently sporadic cases, mutations in the
BMPR2 gene have been identified (Figure 1).
Clinical and hemodynamic characteristics
The mean age at diagnosis of all 231 patients was 43.49
± 12.75 years; 168 patients were females reflecting a
female to male ratio of 2.7:1. BMPR2 mutation carriers
were significantly younger at diagnosis than non-carriers
(Table 1). In three families without any identified muta-
tion in BMPR2, ACVRL1, ENG,o rSMAD8 the mean
age at diagnosis (27.3 y ± 4.78) was significantly lower
than that of the mutation carriers and non-carriers
(HPAH: 38.53 y ± 12.38 and IPAH: 45.78 y ± 11.32, p <
0.01), respectively. Since the mutation carrier status
could not be clarified in these families they have been
excluded for the genotype-phenotype comparison (Fig-
ure 1). Gender distribution was slightly but not signifi-
cantly different in the mutation carriers (female/male
ratio 1.9:1) and non-carriers (ratio 3:1, table 1).
BMPR2 mutation carriers had a significantly higher
mean pulmonary artery pressure (mPAP) and pulmon-
ary vascular resistance (PVR), and a significantly lower
cardiac index (CI) than non-carriers (Table 1). Both
groups did not significantlyd i f f e ri nW H O - f u n c t i o n a l
class, oxygen saturation, heart rate, pulmonary capillary
Figure 1 Genetic disposition of the study population. PAH = pulmonary arterial hypertension, IPAH = idiopathic PAH. The figure shows the
proportion of BMPR2 mutation carriers in the study population, female to male proportion and the mean age at diagnosis.
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Page 3 of 10wedge pressures (PCWP), and systemic arterial systolic
(SASP) and diastolic (SADP) blood pressures (Table 1).
No correlation was seen in our data between truncat-
ing or missense mutation and sex, age of onset, and
hemodynamic measurements (data not shown).
BMPR2 mutations (Table 2)
In 49 HPAH patients heterozygous alterations (46
mutations and 3 unclassified variants) in the BMPR2
gene were identified; 12 mutations and 3 unclassified
variants have been detected for the first time in this
study (Table 2, Figure 2). Table 2 lists all identified
sequence alterations, the type of alteration, their loca-
tion in the gene, and the age at diagnosis. New identi-
fied mutations or unclassified variants of the BMPR2
gene are indicated by asterisks.
Distribution and frequency of BMPR2 mutations
The 49 BMPR2 mutation types identified in the study
population were: 35 point mutations (21 nonsense
mutations and 14 missense mutations), 4 splice site
mutations (all with affected splice donor sites), 4 frame-
shift mutations (small deletions/insertions) and 6 large
deletions. The nonsense and the frameshift mutations
resulted in a premature termination of the protein. The
mutations were distributed throughout the whole
BMPR2 gene with two clusters in a) the extracellular
domain (exons 2-4) and b) the serine/threonine protein
kinase domain (exons 9-11). Four mutations occurred in
more than one independent patient/family: p.R491W
and p.R321X three times, respectively; p.C420Y, p.
R873X and p.R899X two times, respectively.
In 8 of the 209 apparently sporadic cases BMPR2
mutations have been identified and subsequently, thor-
ough analysis of their family members revealed the same
mutation in further asymptomatic members (in 3 par-
ents, 5 children, 2 siblings), indicating that the propor-
tion of sporadic PAH has been over estimated.
New mutations (Figure 2, Table 2)
Five of the 12 identified, to the best of our knowledge
not yet described BMPR2 mutations were nonsense
mutations, 2 frameshift mutations, 2 larger deletions, 2
splice defects, and one missense mutation. The BMPR2
mutations have been identified in exon 2-3, 6, 10, 11,
and 12 (Table 2, Figure 2).
Three of the identified 14 missense mutations are
unclassified sequence variants (p.E386G, p.D487V and
p.A154G) (Table 2 and 3). Their disease causing poten-
tial has not been clearly verified. Analysis of these var-
iants by use of the program MutationTaster [20]
showed that all three variants are predicted to be most
likely disease causing mutations (Table 3). The p.E386G
and the p.D487V variants were both located in the ser-
ine/threonine kinase domain which is a highly con-
served region among different species and suggests an
important role in the function and/or structure of this
region whereas the p.A154G variant was located at the
beginning of the transmembrane domain. The variants
were additionally analysed with the program ESEfinder
Table 1 Clinical characteristics at diagnosis
t-test n = 228
43.49 y ± 12.75
Patients Mutation carrier
n=4 9
Mutation non carrier
n = 179
Age at onset (years) ** 38.53 y ± 12.38 45.78 y ± 11.32
female/male (ratio) 32/17 (1.9:1) 134/45 (3:1)
NYHA at diagnosis III-IV II-IV
Pulmonary hemodynamic parameters
Heart rate per minute * 83.57 ± 11.79 n = 28 77.38 ± 9.07 n = 88
SaO
2 (%) 92.85 ± 3.06 n = 26 92.68 ± 3.29 n = 83
PASP (mm Hg) * 98.5 ± 16.35 n = 26 87.73 ± 18.78 n = 83
PADP (mm Hg) 44.5 ± 7.5 n = 26 36.37 ± 9.22 n = 81
mPAP (mm Hg) *** 62.63 ± 9.92 n = 35 53.44 ± 12.18 n = 135
PCWP 7.08 ± 3.16 n = 26 7.75 ± 2.42 n = 83
SASP (mm Hg) * 118.11 ± 14.34 n = 27 128.13 ± 18.59 n = 86
SADP (mm Hg) 76.5 ± 11.81 n = 27 76.67 ± 10.60 n = 86
CI (Litres/min/m
2) *** 1.67 ± 0.25 n = 31 2.10 ± 0.53 n = 124
PVRI *** 2306.53 ± 770.33 n = 25 1503.25 ± 671.76 n = 116
PVR *** 1519.65 ± 374.65 n = 22 1000.36 ± 456.51 n = 71
* < 0.05
** < 0.01
*** < 0.005
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Patient new Mutation
Location
Exon
Nucleotide Change Amino Acid Change Mutation type Age at diagnosis
K6628 1 c.?_-540_76_?del Del aa1-25? Deletion 50 y
K4808 1 c.?_-540_76_?del Del aa1-25? Deletion 23 y
K9063 1 c.48G > A p.W16X Nonsense 14 y
K4518 * 2 c.91G > T p.E31X Nonsense 45 y
K4452 * 2 c.244C > T p.Q82X Nonsense 39 y
K1893 * 2-3 Del c.77?-c.418? Deletion 27 y
K7369 3 c.353C > T p.C118Y Missense 56 y
K15016 3 c.377A > G p.N126S Missense 28 y
K14629 3 c.377A > G p.N126S Missense 61 y
K7341 3 c.?_248-c.418_?del Deletion 31 y
K2878 * Intron 3 c.418+5G > A Splice defect 25 y
K14983 4 c.439C > T p.R147X Nonsense 49 y
K6834 * 4 c.461C > G p.A154G Missense/unclassified variant 33 y
K7833 4 c.507 C > A p.C169X Nonsense 41 y
K2917 * 4-13 Del c.419? - c.3017? Deletion 30 y
K6565 6 c.631G > A p.R211X Nonsense 51 y
K6686 * 6 c.660insG p. G220fsX224 Frameshift 18 y
K14147 6 c.818T > G p.M273R Missense 59 y
K5429 7 c.961C > T p.R321X Nonsense 27 y
K5633 7 c.961C > T p.R321X Nonsense 50 y
K12665 7 c.961C > T p.R321X Nonsense 69 y
K3771 Intron 8 c.1128+1G > T del aa323-425 Splice defect 40 y
K7892 * 9 c.1157A > G p.E386G Missense/unclassified variant 52 y
K8027 9 c.1259G > A p.C420Y Missense 56 y
K11314 9 c.1258T > C p.C420R Missense 28 y
K15582 * 10 c.1296C > G p.Y432X Nonsense 28 y
K15529 10 c.1297C > T p.Q433X Nonsense 32 y
K4690 10 c.1313-1316delCAGA p.T438fsX472 Frameshift 43 y
MHH09 10 c.1348C > T p.Q450X Nonsense 44 y
MHH52 10 c.1388insA p.P463fsX470 Frameshift 52 y
K5943 10 c.1397G > A p.W466X Nonsense 47 y
K14763 * Intron 10 c.1413+1G > A Splice defect 43 y
K7816 Intron 10 c.1413+3A > T p.G426fsX453 Splice defect 45 y
K12666 * 11 c.1460A > T p.D487V Missense/unclassified variant 42 y
K6717 11 c.1471C > T p.R491W Missense 70 y
K6361 11 c.1471C > T p.R491W Missense 40 y
K6201 11 c.1471C > T p.R491W Missense 30 y
K11744 11 c.1472G > A p.R491Q Missense 26 y
K5590 11 c.1483C > T p.Q495X Nonsense 35 y
K7936 * 11 c.1523G > A p.W508X Nonsense 40 y
K13356 11-12 Del c.1414-? _2866+? Deletion 17.25 y
K10005 * 12 c.1598A > G p.H533R Missense 26 y
MHH18 12 c.1750C > T p.R584X Nonsense 62 y
K14424 * 12 c.2308delC p.R770fsX771 Frameshift 29 y
K12298 12 c.2617C > T p.R873X Nonsense 50 y
K12921 12 c.2617C > T p.R873X Nonsense 53 y
K13213 * 12 c.2626C > T p.Q876X Nonsense 26 y
K8521 12 c.2695C > T p.R899X Nonsense 34 y
K10327 12 c.2695C > T p.R899X Nonsense 19 y
New identified mutations are indicated by asterisks (*)
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have an effect on exonic splicing. According to this ana-
lysis, the p.A154G and p.D487V variants had no effect
on ESE binding sites whereas the p.E386G variant
resulted in loss of 1 SF2/ASF- and 1 SRp40-site, respec-
tively which might have an influence on the correct
splicing [Table 3].
Clinical characterization of patients with familial PAH but
no detectable mutation
Only in 3 out of the 22 families with HPAH (13.6%,
Figure 3) examination of the BMPR2 gene (promoter
and coding regions including flanking intronic regions)
and the coding regions of the ACVRL1, ENDOGLIN,
and the SMAD8 genes did not reveal any defect.
Especially, no point mutations or gross deletions/dupli-
cations were detectable.
In the affected members of all three families PAH has
been diagnosed very early (mean age: 27.3 y ± 4.78) and
was characterised by a very severe and rapid progressive
clinical phenotype (mean hemodynamic values of the
index patients catheterization at diagnosis were: mPAP:
56.3 ± 13.22 mmHg; PCWP: 7.7 ± 2.05 mmHg; CI: 2.01
± 0.47; mean PVR 812 ± 68 dyn; heart rate 91.7 ± 9.43
beats/min). Although no mutations could be identified
in the coding regions of the investigated genes there
might be defects located in deeper intronic regions
which could not be detected by conventional analysis
methods or in other, until now, not identified genes par-
ticipating in the BMPR2 signalling pathway.
Figure 2 Location of the new identified sequence alterations (mutations and/or unclassified variants). The figure shows the location of
all newly identified mutations/unclassified variants through the BMPR2 transcript. Larger deletions are shown as line below the transcript, point
mutations (nonsense and missense), splice site mutations and frameshift mutations are marked above the transcript as arrows, boxes represent
exons, and colours of the boxes represent the different domains. Unclassified sequence alterations are highlighted in green and a dotted arrow.
Mutations which are detected multiple times are only shown once. The mutations are widely distributed throughout the whole gene but two
clusters are recognisable: cluster 1 lies in the extracellular domain (exons 2-4) whereas cluster 2 comprises exons 9 to 11 (serine/threonine
protein kinase domain).
Table 3 Analysis of the Unclassified BMPR2 Sequence Variants by use of computer prediction programs
Unclassified
variant
Localization MutationTaster
prediction
Conservation across
different species
ESEfinder
prediction
Clinical classification according
to family history
p.A154G Transmembrane
domain
Disease causing conserved Not affected IPAH
p.E386G Serine/threonine
kinase domain
Disease causing conserved SF2/ASF-& SRp40-
site affected
IPAH
p.D487V Serine/threonine
kinase domain
Disease causing conserved Not affected PAH with familial history
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The male index patient (II:4) in this family presented
first symptoms at age of 31 years and died early at an
age of 33 years due to sudden right heart failure after an
infection, two months after PAH was diagnosed. About
20 years later his children presented for familial screen-
ing assessment in Heidelberg. This analysis revealed a
severe PAH in his two daughters (III:2, III:3). They have
been early listed for double lung transplantation, which
has been successfully performed 2 years after diagnosis.
Family S1644
The female index patient (III:1) of this family was inva-
sively diagnosed at an age of 22 years. She was severely
affected with NYHA class III, severely impaired right
ventricular function and hemodynamic values (heart
rate per min: 85; mPAP: 75 mmHg; PCWP: 8 mmHg;
CI: 2.0). Her sister (III:2) died very young (age 22 years)
because of PAH, no DNA sample was available. She had
dyspnoea from early childhood on and was initially
diagnosed as bronchial asthma although no asthma
attacks had occurred. The father also died quite young
with an age of 47 years because of an accident and
could not be examined. No other family members
showed signs of PAH. Sequence and MLPA analysis
were both negative for mutations or deletion/duplication
in all investigated genes (Figure 3).
K8139A
A rapid progressive clinical phenotype has been detected
in this family as well. The male index patient (II:2)
showed first symptoms of PAH at an age of 33 years
which was finally confirmed by right heart catheteriza-
tion at age of 34 years (heart rate per min: 105; pulmon-
ary arterial systolic pressure: 68 mmHg; pulmonary
arterial diastolic pressure: 36 mmHg; mPAP: 46 mmHg;
PCWP: 5 mmHg; SASP: 85 mmHg; SADP: 60 mmHg;
CI: 1.44; PVR: 744 dyn). He presented with NYHA class
III-IV, severely impaired right ventricular function and
died finally at the age of 38 years although he has
Figure 3 Pedigree trees of familial PAH cases without mutation. The figure represents pedigree trees of familial cases without mutation in
BMPR2, ACVRL1, ENG, and SMAD8 (family S1490; family S1644 and family K8139). The index patient of each family is marked by an arrow. The
father of the index patients in family S1644 also died quite young with an age of 47 due to an accident.
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nous prostacyclin. He had refused the listing for lung
transplantation. His affected older brother (II:1) died
also very young (age 26 years) because of PAH within
three months after appearance of the first symptoms.
No DNA sample was available from him. The father
(I:1) died at age of 68 years due to an apoplexy. The
familial screening assessment revealed no PAH in any
other family member so far (Figure 3).
Discussion
In this study, we confirmed previous findings that
BMPR2 mutation carriers are younger at diagnosis with
a more severe hemodynamic compromise in a large pro-
spectively assessed cohort of patients with confirmed
PAH. Furthermore, we identified 12 to the best of our
knowledge not yet described BMPR2 mutations and 3
unclassified sequence variants.
The study obtained BMPR2 mutations in 86.4% of
HPAH patients with a positive family history and in
14.4% of patients with apparently sporadic disease. Only
in 3 out of 22 families with confirmed HPAH (13.6%)
no genetic defect could be detected. This result suggests
that with the increasing knowledge on BMPR2 sequence
alterations and the improving diagnostic genetic techni-
ques the rate of identifiable genetic defects in familial
PAH might be even higher ( > 80%) than previously
suggested (≈ 70%) [1,7].
BMPR2 mutations and clinical phenotype
Previous data indicated that having BMPR2 mutations is
associated with a more aggressive form of PAH based
on an earlier age at diagnosis and more severe hemody-
namic [6,12-15]. Although survival was similar in muta-
tion carriers and non-carriers, patients with BMPR2
mutation were more likely to be treated with parenteral
prostacyclin therapy or to undergo lung transplantation
[13]. Worse hemodynamic parameters [12] and reduced
vasoreactivity [6,12,14-16] have been described in PAH-
patients with non-synonymous BMPR2 mutations. The
study performed by Rosenzweig et al [12] included chil-
dren and showed a significant lower cardiac index but
no significantly higher mPAP or PVR. No significantly
differences in the hemodynamic parameters of mutation
carriers vs. non-carriers have been found by Dewachter
et al [23]. They suggested this might be due to the small
number of patients (n = 28) in this study [23].
However, some studies have been retrospective in
design. Our study has analysed the impact of BMPR2
mutations on the age at diagnosis and hemodynamic
parameters for the first time in a prospective design and
confirms the findings of the previous studies [6,12,14,15].
Due to the limited number of patients carrying a
BMPR2 mutation most studies do not allow to
sufficiently correlate distinct mutation types with clinical
presentation. Austin et al. [17] showed that PAH
patients carrying a truncating mutation in the BMPR2
gene developed a more severe disease than patients
without truncating mutation. No correlation was seen in
our data between truncating mutation and gender, age
of onset, and hemodynamic values. This is in concor-
dance with the results of the French PAH registry [15].
Since occurrence of BMPR2 mutations obviously influ-
ences the clinical phenotype genetic testing may become
of increasing clinical relevance. Patients with BMPR2
mutation tend to a more severe clinical phenotype and
might be followed more closely. Clinical assessment of
family members [11,24] might be therefore especially of
importance in patients with detected mutations.
Identification of new BMPR2 mutations
In this study we identified different types of mutations
resulting in a truncated protein which might all interfere
with the downstream signalling of the BMP pathway (for
example by nonsense mediated decay) and activate pro-
liferating pathways [25]. The detected BMPR2 mutations
were distributed throughout the whole gene with 2 clus-
ters as described previously [1,6,15]. Cluster 1 was
located in the extracellular domain (exons 2-4) whereas
cluster 2 comprised exons 9 to 11 (serine/threonine pro-
tein kinase domain). As a consequence the complete
gene should be genetically analysed in clinical routine.
From 49 mutations 12 were newly identified and were
predominantly nonsense mutations. Three newly found
missense mutations were termed unclassified variants
because their disease causing potential has not been
clearly verified until now. Analysis of these variants by
usage of different prediction programs showed that all
three variants are predicted to be most likely disease
causing mutations (Table 3). Two of them (p.E386G and
p.D487V) are located in the serine/threonine kinase
domain which is a highly conserved region among dif-
ferent species and suggests an important role in the
function and/or structure of this region whereas the
third (p.A154G) variant is located at the beginning of
the transmembrane domain. Therefore, all three variants
are predicted to have an impact on the proper function
of the protein.
PAH families without BMPR2 mutation
Three of the 22 familial PAH cases without mutation in
the BMPR2 gene investigated in our study did not reveal
defects of the ACVRL1 gene, the ENG gene, and the
SMAD8 g e n e .W eh a v ee x c l u d e dt h e mf r o mg e n o t y p e -
phenotype analysis to reduce the risk of misclassification
as has been described before [15]. Interestingly, mean
age at diagnosis in this small group was even signifi-
cantly lower as in all other patients. Girerd and
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PAH and hereditary hemorrhagic telangiectasia carrying
a mutation in the ACVRL1 gene. In our families heredi-
tary hemorrhagic telangiectasia and ACVRL1 gene
defects have been excluded. The proportion of patients
with familial aggregation but no detectable BMPR2
mutation was in our study even lower (13.6%) than in
other cohorts (17.6% in the study performed by Austin
et al. and 26.3% in the French registry, respectively
[6,17]). Consequently, it may be assumed that mutations
in the known genes BMPR2, Activin A receptor type II-
like 1, Endoglin,a n dSMAD8 a r en o tt h eo n l yc a u s eo f
the disease. However, in our 3 BMPR2 negative PAH
families it is alternatively possible that these patients
carry mutations in intronic or regulatory regions, which
have not been detected by the used standard techniques.
Thus, in patients with familial aggregation of PAH
BMPR2 mutations are most likely. Genetic testing
including the complete BMPR2 gene may improve risk
stratification in all patients with PAH.
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